Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
CLSD Stock Summary
Top 10 Correlated ETFs
CLSD
In the News

Clearside Biomedical, Inc. (CLSD) Q4 2022 Earnings Call Transcript
Clearside Biomedical, Inc. (NASDAQ:CLSD ) Q4 2022 Earnings Conference Call March 9, 2023 4:30 PM ET Company Participants Jenny Kobin - Investor Relations George Lasezkay - President and Chief Executive Officer Charles Deignan - Chief Financial Officer Conference Call Participants Annabel Samimy - Stifel Serge Belanger - Needham & Company Jonathan Wolleben - JMP Securities Yi Chen - H.C. Wainwright Operator Good day and thank you for standing by and welcome to the Clearside Biomedical Fourth Quarter 2022 Financial Results and Corporate Update Conference Call.

Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Tops Revenue Estimates
Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -23.08% and 111.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Clearside Biomedical to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on Thursday, March 9, 2023
ALPHARETTA, Ga., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its fourth quarter and full year 2022 financial results will be reported on Thursday, March 9, 2023 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

Clearside Biomedical, Inc. (CLSD) Q3 2022 Earnings Call Transcript
Clearside Biomedical, Inc. (NASDAQ:CLSD ) Q3 2022 Earnings Call Transcript November 9, 2022 8:30 AM ET Company Representatives George Lasezkay - Chief Executive Officer Tom Ciulla - Chief Medical Officer, Chief Development Officer Charles Deignan - Chief Financial Officer Dr. Arshad Khanani - Managing Partner at Sierra Eye Associates, Clinical Associate Professor at the University of Nevada Jenny Kobin - Investor Relations Conference Call Participants Andreas Argyrides - Wedbush Annabel Samimy - Stifel John Wolleben - JMP Securities Yi Chen - H.C. Wainwright Serge Belanger - Needham & Company Mayank Mamtani - B.

Clearside Biomedical to Report OASIS Phase 1/2a Clinical Trial Results and Host Conference Call on Wednesday, November 9, 2022 in Conjunction with Third Quarter 2022 Financial Results
Webcast and Conference Call on Wednesday, November 9, 2022 at 8:30 A.M. ET Hosted by Management and Including Key Opinion Leader, Arshad Khanani, M.D. Webcast and Conference Call on Wednesday, November 9, 2022 at 8:30 A.M. ET Hosted by Management and Including Key Opinion Leader, Arshad Khanani, M.D.

Clearside Biomedical to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Wednesday, November 9, 2022
ALPHARETTA, Ga., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its third quarter 2022 financial results will be reported on Wednesday, November 9, 2022 before the open of the financial markets. Management will host a webcast and conference call at 8:30 a.m. Eastern Time to discuss the results and provide a corporate update.

Clearside Biomedical to Present Corporate Overview and Upcoming Catalysts at Eyecelerator at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting
CLS-AX Wet AMD Clinical Trial Data from OASIS Cohorts 3 & 4 Expected in November 2022 CLS-AX Wet AMD Clinical Trial Data from OASIS Cohorts 3 & 4 Expected in November 2022

Clearside Biomedical to Present at the Ophthalmology Futures Retina Forum 2022
ALPHARETTA, Ga., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer will present a company overview and participate in an industry panel virtually during the Ophthalmology Futures Retina Forum 2022 on August 31, 2022.

Clearside Biomedical Inc (CLSD) CEO George Lasezkay on Q2 2022 Results - Earnings Call Transcript
Clearside Biomedical Inc (NASDAQ:CLSD ) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants Jenny Kobin - Head of IR George Lasezkay - President, CEO and Director Tom Ciulla - Chief Medical Officer and Chief Development Officer Charles Deignan - CFO Conference Call Participants Stacy Lee - Stifel Rohit Bhasin - Needham & Company Yi Chen - H.C. Wainwright William Wood - B.

Clearside Biomedical to Participate in Three Upcoming Investor Conferences in August 2022
ALPHARETTA, Ga., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that management will participate in the following investor conferences in August 2022:
CLSD Financial details
CLSD Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 0 | 0.06 | 0.17 | 0.64 | 0 | |
Net income per share | -2.69 | -0.81 | -0.39 | 0.01 | 0 | |
Operating cash flow per share | -2.58 | -0.71 | -0.28 | -0.23 | 0 | |
Free cash flow per share | -2.58 | -0.71 | -0.28 | -0.23 | 0 | |
Cash per share | 1.33 | 0.59 | 0.37 | 0.65 | 0.8 | |
Book value per share | 0.77 | 0.29 | 0.19 | 0.82 | 0.18 | |
Tangible book value per share | 0.77 | 0.29 | 0.19 | 0.82 | 0.18 | |
Share holders equity per share | 0.77 | 0.29 | 0.19 | 0.82 | 0.18 | |
Interest debt per share | 0.32 | 0.14 | 0.04 | 0.01 | 0.02 | |
Market cap | 32.88M | 110.7M | 127.43M | 127.89M | 67.43M | |
Enterprise value | 34.82M | 93.61M | 112.12M | 98.13M | 20.46M | |
P/E ratio | -0.4 | -3.6 | -7 | 340.14 | -2.05K | |
Price to sales ratio | 1.1K | 50.94 | 16.14 | 4.32 | 0 | |
POCF ratio | -0.42 | -4.09 | -9.71 | -11.92 | -5.05K | |
PFCF ratio | -0.41 | -4.09 | -9.67 | -11.92 | -4.95K | |
P/B Ratio | 1.39 | 9.92 | 14.54 | 3.37 | 6.36 | |
PTB ratio | 1.39 | 9.92 | 14.54 | 3.37 | 6.36 | |
EV to sales | 1.16K | 43.08 | 14.2 | 3.32 | 0 | |
Enterprise value over EBITDA | -0.42 | -3.06 | -6.22 | 177.13 | -690.91 | |
EV to operating cash flow | -0.44 | -3.46 | -8.55 | -9.14 | -1.53K | |
EV to free cash flow | -0.44 | -3.46 | -8.51 | -9.14 | -1.5K | |
Earnings yield | -2.52 | -0.28 | -0.14 | 0 | 0 | |
Free cash flow yield | -2.41 | -0.24 | -0.1 | -0.08 | 0 | |
Debt to equity | 0.87 | 1.4 | 1.2 | 0.13 | 3.84 | |
Debt to assets | 0.46 | 0.58 | 0.55 | 0.11 | 0.79 | |
Net debt to EBITDA | -0.02 | 0.56 | 0.85 | -53.72 | 1.59K | |
Current ratio | 4.1 | 2.31 | 1.82 | 9.08 | 8.54 | |
Interest coverage | 0 | 0 | 0 | 0 | -9.07 | |
Income quality | 0.96 | 0.88 | 0.72 | -28.55 | 0.41 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 489.47 | 7.74 | 1.36 | 0.39 | 0 | |
Research and developement to revenue | 2.28K | 7.21 | 1.91 | 0.63 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0.02 | |
Capex to revenue | -2.93 | -0.01 | -0.01 | 0 | 0 | |
Capex to depreciation | -0.47 | -0.12 | -0.31 | 0 | -1.7 | |
Stock based compensation to revenue | 159.5 | 2.12 | 0.46 | 0.17 | 0 | |
Graham number | 6.83 | 2.3 | 1.29 | 0.39 | 0.05 | |
ROIC | -3.92 | 1.54 | 1.04 | 0.03 | 0 | |
Return on tangible assets | -1.88 | -1.15 | -0.94 | 0.01 | 0 | |
Graham Net | 0.66 | 0.18 | 0.14 | 0.71 | 0.13 | |
Working capital | 32.47M | 14.32M | 8.18M | 37.5M | 43.62M | |
Tangible asset value | 23.62M | 11.16M | 8.76M | 37.98M | 10.61M | |
Net current asset value | 22.44M | 9.6M | 7.56M | 37.21M | 8.71M | |
Invested capital | 0.42 | 0.49 | 0.23 | 0.02 | 0.12 | |
Average receivables | 0 | 0 | 0 | 5M | 5M | |
Average payables | 6.13M | 4.07M | 1.64M | 1.47M | 995.5K | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 123.42 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 1.88M | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 2.96 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -3.51 | -2.76 | -2.08 | 0.01 | 0 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2022-12-31 for Q4
Metric | History | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 0.37 | 0.01 | 0.01 | 0 | 0 | |
Net income per share | 0.31 | -0.13 | -0.13 | -0.13 | 0.39 | |
Operating cash flow per share | 0.08 | 0.06 | -0.09 | -0.1 | 0.13 | |
Free cash flow per share | 0.08 | 0.06 | -0.09 | -0.11 | 0.13 | |
Cash per share | 0.51 | 0.57 | 0.48 | 0.89 | 0.8 | |
Book value per share | 0.64 | 0.53 | 0.42 | 0.31 | 0.18 | |
Tangible book value per share | 0.64 | 0.53 | 0.42 | 0.31 | 0.18 | |
Share holders equity per share | 0.64 | 0.53 | 0.42 | 0.31 | 0.18 | |
Interest debt per share | 0.01 | 0.01 | 0.01 | 0.03 | 0 | |
Market cap | 164.09M | 137.55M | 88.42M | 68.01M | 67.43M | |
Enterprise value | 134.33M | 103.77M | 59.89M | 15.04M | 20.46M | |
P/E ratio | 2.19 | -4.5 | -2.83 | -2.17 | 0.73 | |
Price to sales ratio | 7.53 | 396.39 | 230.26 | 0 | 0 | |
POCF ratio | 32.47 | 35.53 | -16.24 | -10.99 | 8.71 | |
PFCF ratio | 32.47 | 35.53 | -16.24 | -10.73 | 8.54 | |
P/B Ratio | 4.32 | 4.34 | 3.5 | 3.67 | 6.36 | |
PTB ratio | 4.32 | 4.34 | 3.5 | 3.67 | 6.36 | |
EV to sales | 6.16 | 299.04 | 155.96 | 0 | 0 | |
Enterprise value over EBITDA | 7.16 | -13.66 | -7.7 | -2.32 | 0.94 | |
EV to operating cash flow | 26.58 | 26.81 | -11 | -2.43 | 2.64 | |
EV to free cash flow | 26.58 | 26.81 | -11 | -2.37 | 2.59 | |
Earnings yield | 0.11 | -0.06 | -0.09 | -0.12 | 0.34 | |
Free cash flow yield | 0.03 | 0.03 | -0.06 | -0.09 | 0.12 | |
Debt to equity | 0.13 | 0.14 | 0.22 | 2 | 3.84 | |
Debt to assets | 0.11 | 0.12 | 0.18 | 0.67 | 0.79 | |
Net debt to EBITDA | -1.59 | 4.45 | 3.67 | 8.16 | -2.15 | |
Current ratio | 9.08 | 8.49 | 5.56 | 10.54 | 8.54 | |
Interest coverage | 0 | 0 | 0 | -5.18 | -17.14 | |
Income quality | 0.27 | -0.51 | 0.7 | 0.79 | 0.33 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.14 | 9.96 | 7.27 | 0 | 0 | |
Research and developement to revenue | 0.18 | 13.07 | 14.14 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0.03 | 0.02 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | -3.97 | -1.26 | |
Stock based compensation to revenue | 0.06 | 3.77 | 3.53 | 0 | 0 | |
Graham number | 2.12 | 1.23 | 1.11 | 0.95 | 1.24 | |
ROIC | -0.99 | 0.22 | 0.26 | 0.13 | -0.48 | |
Return on tangible assets | 0.44 | -0.21 | -0.25 | -0.14 | 0.45 | |
Graham Net | 0.55 | 0.5 | 0.39 | 0.27 | 0.13 | |
Working capital | 37.5M | 31.12M | 24.6M | 49.66M | 43.62M | |
Tangible asset value | 37.98M | 31.7M | 25.25M | 18.55M | 10.61M | |
Net current asset value | 37.21M | 30.92M | 24.49M | 17.72M | 8.71M | |
Invested capital | 0.02 | 0.02 | 0.02 | 0.02 | 0.12 | |
Average receivables | 5M | 5M | 61.5K | 123K | 61.5K | |
Average payables | 858.5K | 1.17M | 2.02M | 2.19M | 1.39M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 41.29 | 0 | 28.83 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 463.24K | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 2.18 | 0 | 3.12 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 0.49 | -0.24 | -0.31 | -0.42 | 2.19 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
CLSD Frequently Asked Questions
What is Clearside Biomedical, Inc. stock symbol ?
Clearside Biomedical, Inc. is a US stock , located in Alpharetta of Ga and trading under the symbol CLSD
What is Clearside Biomedical, Inc. stock quote today ?
Clearside Biomedical, Inc. stock price is $0.97 today.
Is Clearside Biomedical, Inc. stock public?
Yes, Clearside Biomedical, Inc. is a publicly traded company.